Literature DB >> 12167618

Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.

Vita Golubovskaya1, Lucia Beviglia, Li-Hui Xu, H Shelton Earp, Rolf Craven, William Cance.   

Abstract

The focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) are protein-tyrosine kinases that are overexpressed and activated in human breast cancer. To determine the role of EGFR and FAK survival signaling in breast cancer, EGFR was stably overexpressed in BT474 breast cancer cells, and each signaling pathway was specifically targeted for inhibition. FAK and EGFR constitutively co-immunoprecipitated in EGFR-overexpressing BT474 cells. In low EGFR-expressing BT474-pcDNA3 vector control cells, inhibition of FAK by the FAK C-terminal domain caused detachment and apoptosis via pathways involving activation of caspase-3 and -8, cleavage of poly(ADP-ribose) polymerase, and caspase-3-dependent degradation of AKT. This apoptosis could be rescued by the dominant-negative Fas-associated death domain, indicating involvement of the death receptor pathway. EGFR overexpression did not inhibit detachment induced by the FAK C-terminal domain, but did suppress apoptosis, activating AKT and ERK1/2 survival pathways and inhibiting cleavage of FAK, caspase-3 and -8, and poly(ADP-ribose) polymerase. Furthermore, this protective effect of EGFR signaling was reversed by EGFR kinase inhibition with AG1478. In addition, inhibition of FAK and EGFR in another breast cancer cell line (BT20) endogenously overexpressing these kinases also induced apoptosis via the same mechanism as in the EGFR-overexpressing BT474 cells. The results of this study indicate that dual inhibition of FAK and EGFR signaling pathways can cooperatively enhance apoptosis in breast cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167618     DOI: 10.1074/jbc.M205002200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Authors:  Vita M Golubovskaya; Sheila Figel; Baotran T Ho; Christopher P Johnson; Michael Yemma; Grace Huang; Min Zheng; Carl Nyberg; Andrew Magis; David A Ostrov; Irwin H Gelman; William G Cance
Journal:  Carcinogenesis       Date:  2012-03-07       Impact factor: 4.944

2.  FERM domain interaction promotes FAK signaling.

Authors:  Jill M Dunty; Veronica Gabarra-Niecko; Michelle L King; Derek F J Ceccarelli; Michael J Eck; Michael D Schaller
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 3.  Integrin signaling and mammary cell function.

Authors:  Franziska Schatzmann; Rebecca Marlow; Charles H Streuli
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

4.  Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Authors:  Baotran Ho; Gretchen Olson; Sheila Figel; Irwin Gelman; William G Cance; Vita M Golubovskaya
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

5.  Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer.

Authors:  Po-Kai Chuang; Michael Hsiao; Tsui-Ling Hsu; Chuan-Fa Chang; Chung-Yi Wu; Bo-Rui Chen; Han-Wen Huang; Kuo-Shiang Liao; Chen-Chun Chen; Chi-Long Chen; Shun-Min Yang; Chiung Wen Kuo; Peilin Chen; Ping-Tzu Chiu; I-Ju Chen; Jiann-Shiun Lai; Cheng-Der Tony Yu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

6.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 7.  Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Authors:  William G Cance; Elena Kurenova; Timothy Marlowe; Vita Golubovskaya
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

8.  Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Authors:  Vita M Golubovskaya; Grace Huang; Baotran Ho; Michael Yemma; Carl D Morrison; Jisook Lee; Brian P Eliceiri; William G Cance
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

9.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

10.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.